Discussing RA: Real-world evaluation of JAKi efficacy, persistence, and cardiovascular safety in RA
The IMID Forum
- Published
- November 27, 2025
- Duration
- 9:45
- Summary source
- description
- Last updated
- Jun 21, 2026
Discusses Join Professor Iain McInnes for the latest episode of Discussing RA on The Immune-Mediated Inflammat…
Summary
Join Professor Iain McInnes for the latest episode of Discussing RA on The Immune-Mediated Inflammatory Disease Forum. In this episode, he will review two papers. The first paper, by Hernández-Hernández et al. looks at clinical and demographic factors associated with UPA treatment persistence and assesses how cardiovascular risk minimization measures have…
Intelligent report
Sign in to read teasers, or upgrade to Research Pro to commission a new dossier for this episode. Learn more →
Show notes
Join Professor Iain McInnes for the latest episode of Discussing RA on The Immune-Mediated Inflammatory Disease Forum. In this episode, he will review two papers. The first paper, by Hernández-Hernández et al. looks at clinical and demographic factors associated with UPA treatment persistence and assesses how cardiovascular risk minimization measures have impacted UPA prescription patterns. The second paper by Nozaki et al. evaluates the clinical efficacy and continuation rates of JAK inhibitors